Joseph Schwartz
Stock Analyst at Leerink Partners
(4.95)
# 142
Out of 4,692 analysts
1311
Total ratings
54.6%
Success rate
32.9%
Average return
Main Sectors:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Upgraded: Buy | $6 → $1 | $0.17 | +488.24% | 36 | Jul 27, 2026 | |
| QNCX Quince Therapeutics | Initiated Coverage: Buy | $80 | $32.57 | +145.62% | 1 | Jun 24, 2026 | |
| QURE uniQure | Reiterated: Buy | $60 → $70 | $48.68 | +43.80% | 62 | Jun 17, 2026 | |
| EWTX Edgewise Therapeutics | Reiterated: Buy | $52 | $41.77 | +24.49% | 50 | Jun 16, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintained: Buy | $88 → $95 | $84.95 | +11.83% | 46 | Jun 11, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $225 → $305 | $263.04 | +15.95% | 72 | Jun 2, 2026 | |
| FULC Fulcrum Therapeutics | Downgraded: Hold | $24 → $4 | $3.89 | +2.83% | 37 | Jun 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Hold | $60 → $62 | $65.23 | -4.95% | 90 | May 18, 2026 | |
| SPRB Spruce Biosciences | Reiterated: Buy | $160 → $120 | $58.97 | +103.49% | 32 | May 15, 2026 | |
| ANTX AN2 Therapeutics | Upgraded: Buy | $1 → $9 | $5.55 | +62.16% | 23 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $25 | $13.32 | +87.69% | 1 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27.78 | $13.01 | +113.55% | 1 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 → $25 | $4.90 | +410.20% | 31 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 | $21.03 | -28.67% | 107 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $26.57 | +88.18% | 9 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $66.28 | - | 87 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $25.21 | - | 69 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $34.61 | +9.79% | 37 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.13 | - | 50 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $2 | $0.2668 | +649.63% | 31 | Dec 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $9.58 | +108.77% | 45 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $16 | $16.11 | -0.68% | 52 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $5 → $14 | $15.09 | -7.22% | 29 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $115 | $111.93 | +2.74% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $54 | $69.54 | -22.35% | 33 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $121.82 | - | 63 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $3.82 | n/a | 22 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $2.99 | n/a | 29 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $1.22 | n/a | 29 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 | $3.63 | n/a | 19 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $14 | $288.24 | n/a | 1 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $150 → $30 | $9.28 | n/a | 10 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $40 → $34 | $60.36 | n/a | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $147.75 | n/a | 28 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $429.88 | n/a | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $8.44 | n/a | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $31 → $4 | $57.89 | n/a | 16 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $356.02 | n/a | 1 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52.79 | $229.21 | n/a | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $30 | $1.09 | n/a | 2 | Jan 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 → $23 | $12.73 | n/a | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $12 | $2.13 | n/a | 5 | Sep 26, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $121 → $126 | $510.38 | n/a | 4 | Apr 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.82 | n/a | 11 | Nov 13, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.071 | n/a | 5 | Nov 10, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $14 | $4.91 | n/a | 6 | Nov 10, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $0.214 | n/a | 1 | Mar 8, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $664 | $799.08 | n/a | 7 | Oct 26, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $512 → $425 | $216.65 | n/a | 3 | Sep 15, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 → $8 | $70.91 | n/a | 3 | May 19, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $13.88 | n/a | 6 | Oct 30, 2013 |
Gossamer Bio
Jul 27, 2026
Upgraded: Buy
Price Target: $6 → $1
Current: $0.17
Upside: +488.24%
Quince Therapeutics
Jun 24, 2026
Initiated Coverage: Buy
Price Target: $80
Current: $32.57
Upside: +145.62%
uniQure
Jun 17, 2026
Reiterated: Buy
Price Target: $60 → $70
Current: $48.68
Upside: +43.80%
Edgewise Therapeutics
Jun 16, 2026
Reiterated: Buy
Price Target: $52
Current: $41.77
Upside: +24.49%
Crinetics Pharmaceuticals
Jun 11, 2026
Maintained: Buy
Price Target: $88 → $95
Current: $84.95
Upside: +11.83%
Ascendis Pharma
Jun 2, 2026
Reiterated: Buy
Price Target: $225 → $305
Current: $263.04
Upside: +15.95%
Fulcrum Therapeutics
Jun 2, 2026
Downgraded: Hold
Price Target: $24 → $4
Current: $3.89
Upside: +2.83%
BioMarin Pharmaceutical
May 18, 2026
Reiterated: Hold
Price Target: $60 → $62
Current: $65.23
Upside: -4.95%
Spruce Biosciences
May 15, 2026
Reiterated: Buy
Price Target: $160 → $120
Current: $58.97
Upside: +103.49%
AN2 Therapeutics
May 15, 2026
Upgraded: Buy
Price Target: $1 → $9
Current: $5.55
Upside: +62.16%
May 15, 2026
Initiated Coverage: Buy
Price Target: $25
Current: $13.32
Upside: +87.69%
Apr 6, 2026
Initiated Coverage: Buy
Price Target: $27.78
Current: $13.01
Upside: +113.55%
Mar 26, 2026
Reiterated: Buy
Price Target: $26 → $25
Current: $4.90
Upside: +410.20%
Mar 25, 2026
Maintained: Hold
Price Target: $15
Current: $21.03
Upside: -28.67%
Mar 25, 2026
Reiterated: Buy
Price Target: $50
Current: $26.57
Upside: +88.18%
Jan 13, 2026
Maintained: Buy
Price Target: n/a
Current: $66.28
Upside: -
Jan 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $25.21
Upside: -
Jan 13, 2026
Reiterated: Buy
Price Target: $38
Current: $34.61
Upside: +9.79%
Dec 31, 2025
Reiterated: Hold
Price Target: n/a
Current: $2.13
Upside: -
Dec 29, 2025
Reiterated: Buy
Price Target: $8 → $2
Current: $0.2668
Upside: +649.63%
Dec 15, 2025
Reiterated: Buy
Price Target: $20
Current: $9.58
Upside: +108.77%
Dec 3, 2025
Downgraded: Hold
Price Target: $12 → $16
Current: $16.11
Upside: -0.68%
Dec 3, 2025
Upgraded: Buy
Price Target: $5 → $14
Current: $15.09
Upside: -7.22%
Nov 10, 2025
Initiated Coverage: Buy
Price Target: $115
Current: $111.93
Upside: +2.74%
Oct 16, 2025
Reiterated: Hold
Price Target: $54
Current: $69.54
Upside: -22.35%
Sep 29, 2025
Reiterated: Buy
Price Target: n/a
Current: $121.82
Upside: -
Aug 15, 2025
Reiterated: Buy
Price Target: $25
Current: $3.82
Upside: n/a
Aug 7, 2025
Maintained: Buy
Price Target: $10
Current: $2.99
Upside: n/a
Aug 12, 2024
Reiterated: Hold
Price Target: $1
Current: $1.22
Upside: n/a
May 7, 2024
Reiterated: Hold
Price Target: $10
Current: $3.63
Upside: n/a
Sep 7, 2023
Maintained: Hold
Price Target: $14
Current: $288.24
Upside: n/a
Aug 18, 2023
Downgraded: Hold
Price Target: $150 → $30
Current: $9.28
Upside: n/a
Feb 3, 2023
Maintained: Hold
Price Target: $40 → $34
Current: $60.36
Upside: n/a
Aug 5, 2022
Reiterated: Buy
Price Target: $30
Current: $147.75
Upside: n/a
Aug 4, 2022
Rated: Hold
Price Target: n/a
Current: $429.88
Upside: n/a
Jul 13, 2022
Maintained: Buy
Price Target: n/a
Current: $8.44
Upside: n/a
Apr 5, 2022
Downgraded: Hold
Price Target: $31 → $4
Current: $57.89
Upside: n/a
May 7, 2021
Downgraded: Sell
Price Target: n/a
Current: $356.02
Upside: n/a
Apr 15, 2021
Maintained: Buy
Price Target: $52.79
Current: $229.21
Upside: n/a
Jan 6, 2021
Downgraded: Hold
Price Target: $5 → $30
Current: $1.09
Upside: n/a
Nov 28, 2018
Initiated Coverage: Buy
Price Target: $37 → $23
Current: $12.73
Upside: n/a
Sep 26, 2017
Maintained: Buy
Price Target: $10 → $12
Current: $2.13
Upside: n/a
Apr 3, 2017
Maintained: Hold
Price Target: $121 → $126
Current: $510.38
Upside: n/a
Nov 13, 2016
Reiterated: Buy
Price Target: n/a
Current: $13.82
Upside: n/a
Nov 10, 2016
Reiterated: Buy
Price Target: $8
Current: $0.071
Upside: n/a
Nov 10, 2016
Reiterated: Buy
Price Target: $12 → $14
Current: $4.91
Upside: n/a
Mar 8, 2016
Maintained: Buy
Price Target: $24
Current: $0.214
Upside: n/a
Oct 26, 2015
Reiterated: Buy
Price Target: $664
Current: $799.08
Upside: n/a
Sep 15, 2015
Maintained: Buy
Price Target: $512 → $425
Current: $216.65
Upside: n/a
May 19, 2014
Initiated Coverage: Buy
Price Target: $20 → $8
Current: $70.91
Upside: n/a
Oct 30, 2013
Downgraded: Hold
Price Target: n/a
Current: $13.88
Upside: n/a